• 1

    Centers for Disease Control and Prevention (CDC). National Kidney Disease Fact Sheet. General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. Atlanta, GA, US Department of Health and Human Services Centers for Disease Control and Prevention, 2014.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    US Renal Data System. USRDS 2015 Annual Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Medicare Improvements for Patients and Providers Act, Pub 1 No. 110–275, 122 Stat 2553, 2008.

  • 4

    Hirth RA, et al.. The initial impact of Medicare’s new prospective payment system for kidney dialysis patents. Am J Kidney Dis 2013; 62:662669.

  • 5

    Palmer SC, Sciancecalepore M, Strippoli GFM. Trial quality in nephrology: How are we measuring up? Am J Kidney Dis 2011; 58:335337.

  • 6

    Morgan S, et al.. The cost of drug development: A systematic review. Health Policy 2011; 100:417.

  • 7

    How the Tufts Center for the Study of Drug Development Pegged the Cost of a New Drug at $2.6 Billion, Boston. The Tufts Center for the Study of Drug Development, 2014.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Avorn J. The $2.6 billion pill—methodological and policy considerations. N Engl Med 2015; 372:18771879.

  • 9

    DiMasi JA, Grabowski HG, Hansen RW. The cost of drug development. New Engl J Med 2015; 372:1972.

  • 10

    Kidney Health Initiative Inaugural Review 2012–2014. https://www.asn-online.org/khi/KHI_YER_2014.pdf.

  • 11

    Thompson A, Lawrence J, Stockbridge N. GFR decline as an end point in trials in CKD: A viewpoint from the FDA. Am J Kidney Dis 2014; 64:836837.

  • 12

    Levey AS, et al.. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:821835.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    European Medicines Agency. Draft Guidelines on the Clinical Investigation of Medicinal Products to Prevent Development/Slow Progression of Chronic Renal Insufficiency (EMA/CHMP/355988/2014).

    • PubMed
    • Search Google Scholar
    • Export Citation

Collaboration among Industry, Regulatory Agencies, and Professional Societies Drives Progress in Treating Kidney Diseases

Jeffrey Petersen Jeffrey Petersen, MD, is affiliated with Amgen, and is a member of the Kidney NewsEditorial Board

Search for other papers by Jeffrey Petersen in
Current site
Google Scholar
PubMed
Close
Restricted access
Save